Long-term effect of natalizumab in relapsing-remitting multiple sclerosis: TYSTEN cohort

被引：0
|
作者：
Bigaut, K. [1 ]
Fabacher, T. [2 ]
Kremer, L. [1 ]
Ongagna, J. -C. [1 ]
Kwiat-Kowski, A. [3 ]
Sellal, F. [4 ]
Ferriby, D. [5 ]
Courtois, S. [6 ]
Vermersch, P. [7 ]
Collongues, N. [1 ]
Zephir, H. [7 ]
De Seze, J. [1 ]
Outteryck, O. [7 ]
机构：
[1] Hop Univ Strasbourg, Dept Neurol, Strasbourg, France
[2] Hop Univ Strasbourg, Grp Methode Rech Clin, Strasbourg, France
[3] Grp Hop Inst Catholique Lille, Dept Neurol, Hop St Vincent, Lille, France
[4] Hop Civils Colmar, Dept Neurol, Colmar, France
[5] Ctr Hosp Tourcoing, Dept Neurol, Tourcoing, France
[6] Grp Hosp Reg Mulhouse & Sud Alsace, Dept Neurol, Mulhouse, France
[7] Ctr Hosp Reg Univ Lille, Dept Neurol, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1013
引用
收藏
页码：536 / 536
页数：1
相关论文
共 50 条
  • [41] Long-Term Efficacy, Safety and Tolerability of Ponesimod in Patients with Relapsing-Remitting Multiple Sclerosis
    Freedman, Mark
    Boster, Aaron
    Fernandez, Oscar
    Melanson, Maria
    Pozzilli, Carlo
    D'Ambrosio, Daniele
    Sidorenko, Tatiana
    Olsson, Tomas
    NEUROLOGY, 2013, 80
  • [42] Long-term follow-up of laquinimod in patients with relapsing-remitting multiple sclerosis
    Comi, G.
    Vollmer, T. L.
    Lublin, F. D.
    Dadon, Y.
    Gorfine, T.
    Davis, M. D.
    Sorensen, P. S.
    Knappertz, V.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 122 - 123
  • [43] Long-term MRI observations of childhood-onset relapsing-remitting multiple sclerosis
    Balássy, C
    Bernert, G
    Wöber-Bingöl, C
    Csapó, B
    Kornek, B
    Széles, J
    Fleischmann, D
    Prayer, D
    NEUROPEDIATRICS, 2001, 32 (01) : 28 - 37
  • [44] The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis
    Derfuss, T.
    Sastre-Garriga, J.
    Montalban, X.
    Rodegher, M.
    Wuerfel, J.
    Gaetano, L.
    Tomic, D.
    Azmon, A.
    Wolf, C.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (01)
  • [45] Cognitive reserve predicts long-term cognitive trajectories in relapsing-remitting multiple sclerosis
    Maggi, Gianpaolo
    Altieri, Manuela
    Risi, Mario
    Rippa, Valentina
    Borgo, Riccardo Maria
    Lavorgna, Luigi
    Bonavita, Simona
    Buonanno, Daniela
    D'Ambrosio, Alessandro
    Bisecco, Alvino
    Santangelo, Gabriella
    Tessitore, Alessandro
    Gallo, Antonio
    MULTIPLE SCLEROSIS JOURNAL, 2025, 31 (01) : 107 - 116
  • [46] Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis
    Paul L. McCormack
    Drugs, 2013, 73 : 1463 - 1481
  • [47] Efficacy and safety of natalizumab as escalation therapy in relapsing-remitting multiple sclerosis
    Putzki, Norman
    Kiriaki, Kollia
    Katsarava, Zaza
    Woods, Sophia
    Give, Ezinne
    Diener, H.
    NEUROLOGY, 2008, 70 (11) : A90 - A90
  • [48] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [49] Natalizumab arrests cortical atrophy progression in relapsing-remitting multiple sclerosis
    Rinaldi, F.
    Calabrese, M.
    Mattisi, I.
    Seppi, D.
    Puthenparampil, M.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S195 - S196
  • [50] Course of relapsing-remitting multiple sclerosis before, during and after natalizumab
    Kaufman, Michael D.
    Lee, R.
    Norton, H. J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (04) : 490 - 494
12345